White matter changes: the clinical consequences in the aging population
Longitudinal change of white matter abnormalities
Genetic aspects of microangiopathy-related cerebral damage
Research criteria for subcortical vascular dementia in clinical trials
How can cerebral infarcts and hemorrhages lead todementia?
Vascular aspects in Alzheimer’s disease
Novel imaging technologies in the assessment of cerebral ageing and vascular dementia
Alzheimer disease and neuroinflammation
The immunological microenvironment in the CNS: implications on neuronal cell death and survival
Toxic effector molecules in the pathogenesis of immune-mediated disorders of the central nervous system
Cytokines in CNS disorders: neurotoxicity versus neuroprotection
Do neuronal inclusions kill the cell?
Mechanisms of cell death in neurodegenerative disorders
Estrogens, apoptosis and cells of neural origin
Markers of apoptosis and models of programmed cell death in Alzheimer’s disease
Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease
Genetics of Alzheimer’s disease — routes to the pathophysiology
Secretion of the amyloid precursor protein is elevated isoform specifically by apolipoprotein E4
Alterations in neurotrophins and neurotrophin receptors in Alzheimer’s disease
Genetically altered transgenic models of Alzheimer’s disease
Morphological substrates of mental dysfunction in Lewy body disease: an update
Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach
Understanding the role of estrogen on cognition and dementia
Present and future of Alzheimer therapy
Trials to slow progression and prevent disease onset
Epidemiologic clues to the causes and routes to prevention of Alzheimer disease
Post-transcription modulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived factors
A brain derived peptide preparation reduces the translation dependent loss of a cytoskeletal protein in primary cultured chicken neurons
Neurotrophic effects of Cerebrolysin® in animal models of excitotoxicity
Cerebrolysin® reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection
Clinical experience with Cerebrolysin®
Approach towards an integrative drug treatment of Alzheimer’s disease
Oral Cerebrolysin® enhances brain alpha activity and improves cognitive performance in elderly control subjects.